Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Clinical trial NCT07165951 · RECRUITING
Trial details
- NCT number
- NCT07165951
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-02
- Primary completion
- 2028-05-01
- Enrollment
- 566
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.